DecisionPoint Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

DecisionPoint Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.52K	Buy	3 +1	+50%	+$512	﹤0.01%	446
2026 Q2	$997	Sell	2 -8	-80%	-$3.54K	﹤0.01%	448
2026 Q1	$4.47K	Buy	10 +1	+11%	+$466	﹤0.01%	228
2025 Q4	$4.08K	Hold	9	–	–	﹤0.01%	271
2025 Q3	$3.64K	Hold	9	–	–	﹤0.01%	195
2025 Q2	$4.07K	Buy	+9	New	+$4.15K	﹤0.01%	190

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

DecisionPoint Financial's VRTX Position: Q3 2026 in Review

DecisionPoint Financial increased its Vertex Pharmaceuticals (VRTX) stake by 50% in Q3 2026, buying an estimated $512 and bringing the position to 3 shares worth $1.52K. The position accounts for ﹤0.01% of the portfolio, ranked #446.

DecisionPoint Financial first reported a position in VRTX in Q2 2025 and has held it in 6 quarters since. The position peaked at $4.47K in Q1 2026. 625 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

DecisionPoint Financial held 3 shares of Vertex Pharmaceuticals worth $1.52K as of Q3 2026.
DecisionPoint Financial bought 1 Vertex Pharmaceuticals share in Q3 2026, an estimated $512.
Vertex Pharmaceuticals made up ﹤0.01% of DecisionPoint Financial's portfolio in Q3 2026, its #446 holding.
DecisionPoint Financial first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
DecisionPoint Financial's Vertex Pharmaceuticals position peaked at $4.47K in Q1 2026.
625 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on DecisionPoint Financial's 13F filing for Q3 2026, filed 27 Oct 2026.